BioCentury | Jun 2, 2017
Product Development

Ears wide open

Based on unmet need alone, hearing loss should have been every bit as attractive to investors and drug developers as ophthalmic diseases, which entered a renaissance in the mid-2000s resulting in a multibillion-dollar market for...
BC Week In Review | Mar 31, 2017
Company News

Bionure Farma, Spiral Therapeutics deal

Bionure granted Spiral an option to acquire exclusive, worldwide rights to Bionure’s preclinical serum/glucocorticoid regulated kinase 2 (SGK2) agonists BN201 and BN119 to treat otolaryngology indications. Spiral plans to exercise the option by 3Q17. If...
Items per page:
1 - 2 of 2